Bedrijfsoverzicht
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing transformative therapies specifically designed for the treatment of cancer and rare diseases. The company operates within the Healthcare sector and functions in the Biotechnology industry, positioning itself as a developer of investigational cell therapies such as the lead program TARA-002 currently in Phase II clinical trials. As of the latest reporting period, the firm employs 46 individuals and maintains a market capitalization of $268.26M, with annual revenue data not disclosed in the provided financial records. The current market cap of $268.26M relative to the reported employee count of 46 indicates a capital-intensive business model typical of early-to-mid stage biotechnology firms where significant value is placed on intellectual property and pipeline development rather than established commercial revenue streams. This valuation scale reflects the high-risk, high-reward nature of the biotech sector, where companies often operate with substantial cash reserves to fund clinical progress before achieving commercial profitability.
Financiële gezondheid
The company reports a Net Income of $-57,439,000 over the trailing twelve months, while EBITDA stands at $-64,187,000 and Revenue is not available for the trailing twelve months period. The substantial gap between the reported Net Income of $-57,439,000 and the EBITDA figure of $-64,187,000 reveals a cost structure heavily influenced by non-operating expenses or specific accounting adjustments, as the negative net income is slightly less severe than the EBITDA loss. Free Cash Flow is reported at $-38,476,124, indicating that the company is burning cash at a significant rate which limits immediate financial flexibility and necessitates continued access to capital markets or existing reserves. Regarding profitability metrics, the Gross Margin, Operating Margin, and Profit Margin are all recorded at 0.0%, which indicates that the company has not yet generated commercial revenue sufficient to calculate meaningful margins or that revenue recognition is pending from its clinical programs. The balance sheet shows a Cash position of $155.55M against a Debt load of $3.36M, resulting in a Debt to Equity ratio of 1.71, which suggests a leveraged balance sheet structure relative to equity but with significant cash liquidity to cover obligations. The Current Ratio is an exceptionally high 14.58, indicating robust short-term liquidity and an ability to meet its short-term liabilities with ease using its current assets. Return on Equity is -31.6% and Return on Assets is -20.6%, metrics that reveal management is currently deploying capital to generate losses rather than profits, a common characteristic in the development phase of biotechnology companies before product approval.
Waarderingsbeoordeling
The P/E Ratio (TTM) is not available due to the lack of earnings, while the Forward P/E is listed as -3.57, a negative figure that implies the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The Price to Book ratio is 1.35, indicating that the market values the company at a 35% premium over its book value, which suggests investors are pricing in the potential future value of the drug pipeline despite current losses. Since Revenue is not available, the Price to Sales ratio is N/A, and the EV/EBITDA stands at -1.81, suggesting that traditional valuation multiples based on earnings or sales are not applicable in their standard form due to the company's financial stage. The stock has traded between a 52-Week High of $7.82 and a 52-Week Low of $2.77, and without the current share price explicitly listed in the data, the exact percentage deviation from these bounds cannot be calculated, though the range demonstrates significant price volatility over the last year. The Beta is 1.50, meaning the stock is expected to be 50% more volatile than the broader market, reflecting the inherent high risk associated with clinical-stage biotechnology equities.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates between the two metrics as the underlying revenue data required for the calculation is not provided in the available facts. The Dividend Yield is N/A and the Payout Ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. As a non-dividend payer, Protara Therapeutics reinvests its available cash flow entirely into research, development, and clinical trial activities rather than returning capital to investors. Consequently, the overall growth and income profile is characterized by a complete focus on capital appreciation potential through pipeline advancement rather than current yield or historical earnings growth.